Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
Launched by BAYER · Sep 13, 2005
Trial Information
Current as of June 28, 2025
Completed
Keywords
ClinConnect Summary
This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc. is the sponsor of the trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients in North America have to have been previously enrolled in the original Betaseron trial from 1988-1993
- • Be able to understand the consent form (or have a guardian who can)
- Exclusion Criteria:
- • North American patients cannot be included if they have not participated in the original Betaseron trial from 1988-1993
About Bayer
Bayer is a global healthcare and life sciences company dedicated to advancing health and well-being through innovative research and development. With a strong commitment to improving patient outcomes, Bayer conducts clinical trials across various therapeutic areas, including oncology, cardiology, and women's health. The company leverages cutting-edge science and technology to develop breakthrough therapies, while adhering to the highest standards of ethical practices and regulatory compliance. Through collaboration with healthcare professionals and research institutions, Bayer aims to bring transformative solutions to the market, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Many Locations, Alabama, United States
Many Locations, British Columbia, Canada
Patients applied
Trial Officials
Bayer Study Director
Study Director
Bayer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials